logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Rarecells, Inc. Announces Successful Series A Funding, Reaching $13 Million Raised To Develop Liquid Biopsy Early Cancer Detection Tests

Dec 09, 2021•about 4 years ago

Round Type

series a

New York

Description

Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests.

Company Information

Company

Rarecells

Location

New York, New York, United States

About

Rarecells, Inc. is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests. These tests are based on the ISET® platform technology that is able to extract from blood cancer cells from any type of cancer. Cancer cells extracted by ISET® are then diagnostically identified through immune-morpho-molecular analyses combined with image analyses and AI. This approach is believed to be a significant advancement in the highly sensitive non-invasive detection of cancer's signals providing a powerful tool for early cancer detection through the identification of the first circulating cancer cells.